Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

IOVA

Ранг среди акций #2795
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Цена акции
$14.87
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$6.74B
Изменение (1 день)
4.64%
Изменение (1 год)
555.03%
Страна
US
Торговля Iovance Biotherapeutics, Inc. (IOVA)

Категория

Healthcare
История дроблений акций Iovance Biotherapeutics, Inc. (IOVA)
Акции Iovance Biotherapeutics, Inc. (символ: IOVA) прошли через 2 дроблений.
Последнее дробление произошло Sep 26, 2013.
Одна акция IOVA, купленная до May 26, 2010, сейчас соответствует 0.23999 акциям IOVA.
Список дроблений акций
Год Дробление Коэффициент Суммарный коэффициент
2013-09-26 1:100 x0.01 x0.23999
2010-05-26 23999:1000 x23.999 x23.999
Дробления акций аналогичных компаний или конкурентов
Компания Количество дроблений акций Суммарный коэффициент Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL